Association between Serum Levels of Interleukin-25/Thymic Stromal Lymphopoietin and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease
暂无分享,去创建一个
Tae-Hyung Kim | H. Yoon | C. Rhee | K. Yoo | S. Lim | Sung-Yoon Kang | Sang Hyuk Kim | Joon Young Choi | K. Jung | H. Park
[1] J. Moon,et al. Longitudinal changes in forced expiratory volume in 1 s in patients with eosinophilic chronic obstructive pulmonary disease , 2022, BMC Pulmonary Medicine.
[2] C. Brightling,et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. , 2022, The Lancet. Respiratory medicine.
[3] G. Koppelman,et al. Biologic Therapies for Severe Asthma. , 2022, The New England journal of medicine.
[4] Jian Liu,et al. Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis , 2021, Frontiers in Pharmacology.
[5] M. K. Ruddy,et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. , 2021, The Lancet. Respiratory medicine.
[6] F. Maltais,et al. Update on Asthma–COPD Overlap (ACO): A Narrative Review , 2021, International journal of chronic obstructive pulmonary disease.
[7] I. Pavord,et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO , 2021, International journal of chronic obstructive pulmonary disease.
[8] E. Israel,et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. , 2021, The New England journal of medicine.
[9] S. Park,et al. Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease , 2021, BMC Pulmonary Medicine.
[10] J. Guiot,et al. Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype. , 2021, Cytokine.
[11] L. Koenderman,et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait , 2020, Thorax.
[12] S. Hiles,et al. Disease burden of eosinophilic airway disease: Comparing severe asthma, COPD and asthma–COPD overlap , 2020, Respirology.
[13] P. Kuna,et al. IL-33 Mediated Inflammation in Chronic Respiratory Diseases—Understanding the Role of the Member of IL-1 Superfamily , 2019, Front. Immunol..
[14] Masaki Ikeda,et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.
[15] P. Barnes. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease , 2018, Nature Reviews Immunology.
[16] Yan Li,et al. Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease , 2018, The Journal of Immunology.
[17] I. Pavord,et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.
[18] E. Israel,et al. Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.
[19] M. R. Siddiqui,et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .
[20] D. Kim,et al. Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease , 2017, International journal of chronic obstructive pulmonary disease.
[21] M. Cazzola,et al. The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils , 2016, BioMed research international.
[22] B. Nordestgaard,et al. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.
[23] C. Brightling,et al. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease , 2016, Therapeutic advances in chronic disease.
[24] Dave Singh,et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.
[25] E. Noguchi,et al. Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes , 2011, International journal of chronic obstructive pulmonary disease.
[26] S. Ziegler,et al. Sensing the outside world: TSLP regulates barrier immunity , 2010, Nature Immunology.
[27] C. Corrigan,et al. The Role of Thymic Stromal Lymphopoietin in Allergic Inflammation and Chronic Obstructive Pulmonary Disease , 2010, Archivum Immunologiae et Therapiae Experimentalis.
[28] B. O'connor,et al. Expression and Cellular Provenance of Thymic Stromal Lymphopoietin and Chemokines in Patients with Severe Asthma and Chronic Obstructive Pulmonary Disease1 , 2008, The Journal of Immunology.
[29] D. Robinson,et al. Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of Th2-Attracting Chemokines and Disease Severity1 , 2005, The Journal of Immunology.
[30] D. Postma,et al. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. , 2000, Epidemiology.
[31] Lingyun Wu,et al. Effect of TSLP on the function of platelets and IL-25 in chronic obstructive pulmonary disease , 2019 .